Skip to content

Clinical trials

Mesothelioma, Malignant trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Mesothelioma, Malignant Phase: Not applicable Clear all

23 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20051
20061
20101
20111
20121
20142
20151
20161
20172
20201
20221
20233
20244
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting7
Completed6
Unknown status4
Terminated3
Withdrawn2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Ankara University2
Wake Forest University Health Sciences2
Ain Shams University1
Azienda Ospedaliero-Universitaria di Parma1
Cairo University1
Fox Chase Cancer Center1
Institute of Cancer Research, United Kingdom1
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1
Jonsson Comprehensive Cancer Center1
Kantonsspital Winterthur KSW1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Mesothelioma, Malignant23
Carcinoma, Non-Small-Cell Lung4
Lung Neoplasms3
Mesothelioma3
Breast Neoplasms2
Carcinoma, Bronchogenic2
Colonic Neoplasms2
Colorectal Neoplasms2
Ovarian Neoplasms2
Prostatic Neoplasms2

Trials

Showing 51 to 23 of 23. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.